34966-52-4

Usage

Uses

Used in Pharmaceutical Industry:
ETHYL 3,4-DICHLOROBENZOYLFORMATE is used as an intermediate in the synthesis of various pharmaceuticals. Its role in the production of drugs is crucial, as it aids in the formation of essential chemical structures that contribute to the drugs' therapeutic effects.
Used in Agrochemical Industry:
In the agrochemical sector, ETHYL 3,4-DICHLOROBENZOYLFORMATE is utilized as an intermediate for the synthesis of agrochemicals. It plays a significant part in developing products that protect crops from pests and diseases, thereby ensuring food security and agricultural productivity.
Used as a Reagent in Organic Synthesis:
ETHYL 3,4-DICHLOROBENZOYLFORMATE is employed as a reagent in organic synthesis processes, particularly for the formation of esters and amides. Its ability to participate in these reactions is valuable for creating a wide range of organic compounds used in various industries, including pharmaceuticals, materials science, and chemical research.

InChI:InChI=1/C10H8Cl2O3/c1-2-15-10(14)9(13)6-3-4-7(11)8(12)5-6/h3-5H,2H2,1H3

Upstream product

• 2642-63-9 3',4'-dichloroacetophenone 
• 140-89-6 potassium ethyl xanthogenate 
• 13627-07-1 ethyl 2-(3,4-dichlorophenyl)-2-hydroxyacetate 
• 96605-05-9 C₁₁H₁₁Cl₂NO 
• 64-17-5 ethanol 
• 79175-35-2 3,4-dichlorophenylmagnesium bromide 
• 75716-82-4 imidazol-1-yl-oxo-acetic acid ethyl ester 

Downstream Products

• 1033780-26-5 (E)-cyclopentyloxyimino-(3,4-dichloro-phenyl)-acetic acid ethyl ester 
• 1239279-18-5 (R)-ethyl 2-(3,4-dichlorophenyl)-2-hydroxy-3-nitropropanoate 
• 1239279-22-1 (R)-tert-butyl 2-(3,4-dichlorophenyl)-2-(hydroxymethyl)morpholine-4-carboxylate 
• 1239279-28-7 [2-(3,4-dichlorophenyl)-2-hydroxymethylmorpholin-4-yl]phenylmethanone 
• 1239279-29-8 (R)-(2-(3,4-dichlorophenyl)-2-vinylmorpholino)(phenyl)methanone 
• 1239279-19-6 (R)-ethyl 3-amino-2-(3,4-dichlorophenyl)-2-hydroxypropanoate 
• 1239279-20-9 (R)-ethyl 3-(2-chloroethanamido)-2-(3,4-dichlorophenyl)-2-hydroxypropanoate 
• 1239279-21-0 (R)-ethyl 2-(3,4-dichlorophenyl)-5-oxomorpholine-2-carboxylate 
• 335395-63-6 (R)-(2-(3,4-dichlorophenyl)morpholin-2-yl)methanol 
• 1278598-14-3 [2-(3,4-dichlorophenyl)-2-((Z)-2-methoxyvinyl)morpholin-4-yl]phenylmethanone 
• 1278598-16-5 [2-(3,4-dichlorophenyl)-2-((E)-2-methoxyvinyl)morpholin-4-yl]phenylmethanone 
• 56177-76-5 2-(3,4-dichlorophenyl)-2,2-difluoroacetic acid ethyl ester 
• 1432492-47-1 (R)-[(2S)-2-(3,4-dichlorophenyl)oxetan-2-yl](pyridin-2-yl)methanol hydrochloride salt 
• 1432492-48-2 (R)-((R)-2-(3,4-dichlorophenyl)oxetan-2-yl)(pyridin-2-yl)methanol hydrochloride 

Relevant academic research and scientific papers

Optimization of the Urea Linker of Triazolopyridazine MMV665917 Results in a New Anticryptosporidial Lead with Improved Potency and Predicted hERG Safety Margin

Cryptosporidiosis is caused by infection of the small intestine by Cryptosporidium parasites, resulting in severe diarrhea, dehydration, malabsorption, and potentially death. The only FDA-approved therapeutic is only partially effective in young children and ineffective for immunocompromised patients. Triazolopyridazine MMV665917 is a previously reported anti-Cryptosporidium screening hit with in vivo efficacy but suffers from modest inhibition of the hERG ion channel, which could portend cardiotoxicity. Herein, we describe our initial development of structure-activity relationships of this novel lead series with a particular focus on optimization of the piperazine-urea linker. We have discovered that piperazine-acetamide is a superior linker resulting in identification of SLU-2633, which has an EC50 of 0.17 μM, an improved projected margin versus hERG, prolonged pharmacokinetic exposure in small intestine, and oral efficacy in vivo with minimal systemic exposure. SLU-2633 represents a significant advancement toward the identification of a new effective and safe treatment for cryptosporidiosis.

ARYLACETAMIDE ANALOGS OF PIPERAZINE-[1,2,4]TRIAZOLO[4,3-B]PYRIDAZINES

Provided are compounds with the following structure: Formula (I), and methods of making and using same. The methods of using the compounds may be methods for treating or prophylaxis of a cryptosporidium infection.

Metal-Free Oxidative Esterification of Ketones and Potassium Xanthates: Selective Synthesis of α-Ketoesters and Esters

A novel and efficient oxidative esterification for the selective synthesis of α-ketoesters and esters has been developed under metal-free conditions. In the protocol, various α-ketoesters and esters are available in high yields from commercially available ketones and potassium xanthates. Mechanistic studies have proven that potassium xanthate not only promotes oxidative esterification but also provides an alkoxy moiety for the reaction, which involves the cleavage and reconstruction of C-O bonds.

Exploiting Cofactor Versatility to Convert a FAD-Dependent Baeyer–Villiger Monooxygenase into a Ketoreductase

Cyclohexanone monooxygenases (CHMOs) show very high catalytic specificity for natural Baeyer–Villiger (BV) reactions and promiscuous reduction reactions have not been reported to date. Wild-type CHMO from Acinetobacter sp. NCIMB 9871 was found to possess an innate, promiscuous ability to reduce an aromatic α-keto ester, but with poor yield and stereoselectivity. Structure-guided, site-directed mutagenesis drastically improved the catalytic carbonyl-reduction activity (yield up to 99 %) and stereoselectivity (ee up to 99 %), thereby converting this CHMO into a ketoreductase, which can reduce a range of differently substituted aromatic α-keto esters. The improved, promiscuous reduction activity of the mutant enzyme in comparison to the wild-type enzyme results from a decrease in the distance between the carbonyl moiety of the substrate and the hydrogen atom on N5 of the reduced flavin adenine dinucleotide (FAD) cofactor, as confirmed using docking and molecular dynamics simulations.

Ambient and aerobic carbon-carbon bond cleavage toward α-ketoester synthesis by transition-metal-free photocatalysis

The α-oxoesterification of the CC double bond in readily available enaminones enabling efficient synthesis of α-ketoesters is developed. The reactions showing general tolerance to the reactions of primary and secondary alcohols proceed well under air via Rose Bengal (RB)-based photocatalysis. Particularly, this mild synthetic method has been discovered to tolerate various polyhydroxylated substrates such as phenolic alcohol, diols and triols with an excellent selectivity of mono-oxoesterification. What is more noteworthy is that α-ketoester functionalized 16-dehydropregnenolone acetate resulting from the elaboration on a natural product has been obtained practically.

Asymmetric synthesis of an antagonist of neurokinin receptors: SSR 241586

SSR 241586 is a 2,2-disubstituted morpholine, developed by Sanofi-Aventis, which is active in the treatment of schizophrenia and irritable bowel syndrome (IBS). Different strategies have been studied to synthesize this molecule and among the strategies an

Enantioselective synthesis of SSR 241586 by using an organo-catalyzed Henry reaction

An organo-catalyzed Henry reaction, applied to an α-keto ester, has allowed the enantioselective synthesis of SSR 241586, a 2,2-disubstituted morpholine active in the treatment of schizophrenia and irritable bowel syndrome (IBS).